Figure 2
From: Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
Omallizumab reduced IL-6 secretion in human B cells. B cells were left non-treated (NT), treated with IL-4 + anti-CD40 in the presence or absence of 1 μg/mL omalizumab (Om) or omalizumab alone. After 3 and 7 days, culture supernatant fluid was collected and quantified for IL-6 by ELISA. Data are expressed as the mean ± SEM (n = 6 tonsils). Statistically significant difference (p value) was determined by t-test.